China Resources Sanjiu Medical & Pharmaceutical Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Wen Duo Wu
Chief executive officer
CN¥9.0m
Total compensation
CEO salary percentage | n/a |
CEO tenure | less than a year |
CEO ownership | n/a |
Management average tenure | 3.4yrs |
Board average tenure | 3.2yrs |
Recent management updates
Recent updates
CEO
Wen Duo Wu (50 yo)
Mr. Wen Duo Wu is Chairman of KPC Pharmaceuticals,Inc. from January 22, 2025. He is President of China Resources Sanjiu Medical & Pharmaceutical Co. Ltd.from September 06, 2024 and serves as its Director...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President & Director | less than a year | CN¥9.00m | no data | |
VP, General Counsel | 13.8yrs | CN¥25.59m | 0.013% CN¥ 7.2m | |
Vice President | 9.8yrs | CN¥26.32m | 0.016% CN¥ 8.4m | |
Vice President | 3.4yrs | CN¥24.09m | 0.010% CN¥ 5.4m | |
CFO & Secretary of the Board | less than a year | no data | no data |
Experienced Management: 000999's management team is considered experienced (3.4 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President & Director | less than a year | CN¥9.00m | no data | |
VP, General Counsel | 20.1yrs | CN¥25.59m | 0.013% CN¥ 7.2m | |
Chairman | 7.7yrs | CN¥29.03m | 0.019% CN¥ 10.4m | |
Chairman of the Supervisory Board | 6.5yrs | no data | no data | |
Independent Director | 1.3yrs | CN¥1.41m | no data | |
Non-Independent Director | 3.2yrs | no data | no data | |
Non-Independent Director | 3.2yrs | no data | no data | |
Supervisor | 7.1yrs | no data | no data | |
Director | 2.6yrs | no data | no data | |
Supervisor | 1.8yrs | no data | no data | |
Supervisor | less than a year | no data | no data |
Experienced Board: 000999's board of directors are considered experienced (3.2 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/05/23 16:59 |
End of Day Share Price | 2025/05/23 00:00 |
Earnings | 2025/03/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is covered by 39 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Changming He | BOCI Research Ltd. |
Jessica Li | BofA Global Research |
Shuchang Liu | Changjiang Securities Co. LTD. |